Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Semax regulatory status

Current status of Semax in the United States: HHS interim policy (draft). In sport: WADA status unclear. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Semax?

Regulatory: HHS interim policy (draft)WADA: WADA status unclearVerified: Verified Nov 1, 2026
FDA and compounding
Semax is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax when every condition is met: a single active ingredient only (no blends or stacks), the allowed route (intranasal only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add semax to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADA
WADA status unclear
Access path
  1. Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient semax as a nasal product only on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.
  2. Not available as an FDA approved product; registered prescription drug in Russia.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Full Semax page: evidence, dosing in the literature, and sources

Is semax FDA approved?

No. Semax is not an FDA approved drug, although it is a registered prescription drug in Russia. FDA placed it on the 503A Category 2 list in 2023, and FDA's list dated April 22, 2026 shows the nomination as withdrawn. At the July 24, 2026 compounding advisory committee meeting, FDA's drug center (CDER) recommended against listing it and the committee voted in favor (HHS policy, Appendix B). A committee vote is advisory and is not a U.S. approval. HHS's October 28, 2026 draft enforcement discretion policy is not an approval either: HHS only says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient semax for a named patient on a prescription, under strict conditions. [1] [2] [3] [4] [5]

What is the FDA status of semax in 2026?

HHS interim policy (draft). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds semax as a single-ingredient product by the allowed route (intranasal only), on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. It is not an FDA approval or a 503A bulks listing, it is not binding, and HHS may revisit it; comments are open through November 13, 2026. Before that, semax was in 503A Category 2 from September 2023 until April 22, 2026, when its nomination was withdrawn, and at the July 24, 2026 advisory committee meeting FDA's drug center (CDER) recommended against listing it while the committee voted in favor (HHS policy, Appendix B). Blends and stacks are not covered. [2] [3] [4] [5]

Is semax legal in the US?

There is still no FDA approved semax. Under HHS's October 28, 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a state-licensed pharmacy or licensed physician that compounds single-ingredient semax as a nasal product only on a patient-specific prescription, if every quality and reporting condition is met. The policy is a draft, is not binding, and HHS may revisit it; it is not an approval and does not add semax to the 503A bulks list. Blends and stacks are not covered. State law still applies, and products labeled research use only are still unapproved drugs when sold for human use and are not verified for purity. Its Russian registration does not carry over to the United States. [3] [4] [5] [6]

Is semax banned by WADA?

Unclear. Semax is not named on the WADA Prohibited List, and because it is an approved drug in Russia it does not automatically fall under section S0 for non-approved substances. Athletes should confirm with their anti-doping organization before use. [7]

How has the status of Semax changed over time?

  1. HHS

    HHS draft policy lets licensed pharmacies compound six peptides without enforcement action

    HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.

  2. PCAC

    FDA advisory committee reviews six peptides; FDA's briefing recommends against listing

    At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.

  3. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  4. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Semax and the source of each dated event.

  1. [1]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (503A Category 2 list and nominated but withdrawn substances, current as of April 22, 2026)FDA, 2026
  2. [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  3. [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  4. [4]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history)2026
  5. [5]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
  6. [6]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  7. [7]WADA Prohibited ListWADA, 2026

From the blog